AMS receives approval to start clinical trials for 18F-NaF

AMS became the first company to receive approval to start clinical trials for 18F-NaF from the CFDA. 18F-NaF is used in the diagnosis of bone tumours in PET scans and is already widely used in US, Japan and Europe.

Link to the relevant announcement in Chinese:

http://www.cninfo.com.cn/new/disclosure/detail?plate=szse&stockCode=002675&announcementId=1206451921&announcementTime=2019-07-17